Revelation Partners

Revelation Partners, LLC is a private equity and venture capital firm based in San Francisco, California, founded in 2012. The firm specializes in buyout, direct, and fund of fund investments, primarily focusing on late-stage companies within the healthcare sector. Its investment strategy emphasizes commercial enterprises with proven business models or innovative technologies that have clear clinical and regulatory pathways. Revelation Partners typically invests between $5 million and $30 million, with the capacity to engage in larger deals alongside limited partners. The firm concentrates on medical devices, biopharmaceuticals, healthcare information technology, and healthcare services, often seeking majority stakes in its investments. Additionally, it engages in secondary investments and offers liquidity solutions to existing investors looking to divest.

Michael Boggs

Managing Partner

Garrett Brown

Senior Associate

Doug Fisher

Partner

Keegan Hasson

Senior Associate

Fred Lee

Partner

Fred Lee

Partner

Courtney Munley

Associate

Andrew Olson

Partner, CFO and COO

Rob Rein

Vice President

Liz Staley

Partner and CCO

26 past transactions

Dren Bio

Series B in 2022
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.

Aspen Neuroscience

Series B in 2022
Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing induced pluripotent stem cell therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company aims to create patient-specific restorative cell therapies that can alter the progression of the disease. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By integrating innovative genomic approaches with stem cell biology, Aspen Neuroscience seeks to advance the field of personalized medicine and improve treatment outcomes for patients suffering from Parkinson's disease.

IntelyCare

Series C in 2022
IntelyCare, Inc. provides on-demand staffing services tailored for healthcare organizations, focusing primarily on post-acute care facilities. Established in 2014 and headquartered in Quincy, Massachusetts, the company offers a digital workforce augmentation platform that combines a gig-model application with advanced data science. This platform allows healthcare facilities to optimize staffing levels by efficiently matching nursing professionals with available shifts, thereby addressing the growing gap between workforce supply and demand. Nurses and nursing assistants benefit from the platform by having the flexibility to create their own schedules and select shifts that suit them, promoting a more engaged and productive workforce. IntelyCare serves a variety of clients, including home care agencies, assisted living facilities, long-term care facilities, and rehabilitation hospitals. As a subsidiary of Leerink Revelation Healthcare Fund II GP, LLC, IntelyCare is positioned to revolutionize the healthcare staffing market by filling nursing shifts at a rate three times higher than the industry average.

Gravia

Series E in 2022
Gravie, Inc. operates a health insurance platform that facilitates the comparison and purchase of health insurance plans for individuals, families, and employers. Founded in 2013 and headquartered in Minneapolis, Minnesota, the company provides a comprehensive solution for managing health insurance expenses through its mobile application and website. Gravie allows users to shop for insurance options available on government-run exchanges and directly from insurance companies. The platform also offers tools for employers to design custom benefits plans using a defined contribution approach, enabling them to set a fixed budget for employee health benefits. Additionally, Gravie provides year-round support, financial analysis, and services such as Gravie Care, which assists individuals in managing their healthcare expenses effectively.

Endeavor BioMedicines

Series B in 2022
Endeavor BioMedicines is a clinical-stage company focused on creating innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). The company is developing a small-molecule inhibitor aimed at addressing the underlying causes of this disease. This potential therapy not only seeks to halt the progression of IPF but may also reverse its effects, thereby providing healthcare professionals with precision treatment options for this terminal condition. By targeting the root causes of the disease, Endeavor BioMedicines aims to improve patient outcomes and enhance quality of life for those affected by pulmonary fibrosis.

HotSpot Therapeutics

Series C in 2021
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.

Click Therapeutics

Series B in 2021
Click Therapeutics, Inc. specializes in the engineering, validation, development, and commercialization of digital therapeutic solutions aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012 and based in New York, the company offers innovative digital therapeutics for a range of conditions, including smoking cessation, major depressive disorder, schizophrenia, insomnia, and chronic pain. Its Digital Therapeutics™ are designed to function independently or alongside traditional biomedical treatments, utilizing the Clickometrics® adaptive data science platform to personalize user experiences and enhance engagement. Notably, Click's smoking cessation program has gained widespread access through various payers and providers, while its primary prescription program is advancing into a significant phase III clinical trial for major depressive disorder in adults.

SPR Therapeutics

Series D in 2021
SPR Therapeutics, LLC is a medical device company focused on developing and commercializing interventional pain management therapies. The company specializes in peripheral nerve stimulation (PNS) products, including its flagship Smartpatch system, which provides short-term pain relief following surgeries and for various types of pain such as neuropathic and musculoskeletal pain. Smartpatch is designed for minimally invasive use, allowing for up to 30 days of electrical stimulation to alleviate pain. Additionally, the company offers the Micropulse system for long-term therapy through an implantable PNS solution. SPR Therapeutics aims to provide a non-narcotic alternative to opioids and invasive procedures, emphasizing safety, effectiveness, and affordability in pain management. Founded in 2009 and headquartered in Cleveland, Ohio, the company also has facilities in the Carolinas and Minneapolis.

US Fertility

Private Equity Round in 2021
Operator of a physician practice management firm providing business support services for top-tier fertility programs across the United States. The company offers a variety of technology platforms to effectively manage clinical and business information systems, facilities and operations, finance and accounting, physician recruitment and credentialing, legal, risk management, lab operations, business development, fertility treatment financing programs and other services that support fertility focused domestic and international physician practices to drive innovation and leverage best practices to enhance both the patient experience and treatment outcomes.

Genome Medical

Series C in 2021
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.

Gravia

Series D in 2021
Gravie, Inc. operates a health insurance platform that facilitates the comparison and purchase of health insurance plans for individuals, families, and employers. Founded in 2013 and headquartered in Minneapolis, Minnesota, the company provides a comprehensive solution for managing health insurance expenses through its mobile application and website. Gravie allows users to shop for insurance options available on government-run exchanges and directly from insurance companies. The platform also offers tools for employers to design custom benefits plans using a defined contribution approach, enabling them to set a fixed budget for employee health benefits. Additionally, Gravie provides year-round support, financial analysis, and services such as Gravie Care, which assists individuals in managing their healthcare expenses effectively.

Nuvolo

Series C in 2021
Nuvolo Technologies Corporation offers a cloud-based enterprise asset management platform built on the ServiceNow framework. Established in 2013 and headquartered in Paramus, New Jersey, with additional offices in London, Bulgaria, and India, Nuvolo specializes in life-cycle management solutions for assets in clinics, laboratories, facilities, and manufacturing sectors. The company provides a comprehensive suite of services that includes implementation, support, tracking, reporting, and analytics, aimed at enhancing the user experience for mobile and remote workforces. Known for its commitment to innovation and customer service, Nuvolo has formed strategic partnerships with major firms such as Atos, KPMG, and Unisys to further its mission of becoming a leader in cloud-based enterprise asset management.

SetPoint Medical

Venture Round in 2021
SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for treating chronic inflammatory diseases, including rheumatoid arthritis and Crohn's Disease. The company leverages the Inflammatory Reflex, a natural mechanism that allows the central nervous system to regulate the immune system, which has been extensively studied and documented in scientific literature. SetPoint's proprietary microregulator aims to enhance this reflex through vagus nerve stimulation, offering an alternative treatment option that provides systemic anti-inflammatory effects. The devices are designed to supplement the body's natural responses and are expected to deliver comparable anti-inflammatory potency to leading medications, while potentially offering improved safety and lower costs. Currently, SetPoint is conducting human trials for its technology at multiple centers in Europe.

SomaLogic

Series A in 2020
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

NeuroPace

Private Equity Round in 2020
NeuroPace, Inc. specializes in the design, development, manufacturing, and marketing of implantable devices aimed at treating neurological disorders through responsive stimulation. The company's flagship product, the RNS System, is specifically designed for patients with medically refractory partial epilepsy. This system includes a small implantable neurostimulator that monitors brain activity and delivers electrical pulses to targeted areas to prevent seizures. The RNS System comprises various components, such as depth leads and cortical strip leads for implantation, along with external devices like a programmer that allows healthcare professionals to communicate with the neurostimulator. Founded in 1997, NeuroPace is headquartered in Mountain View, California.

Mission Therapeutics

Venture Round in 2020
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.

Genome Medical

Series B in 2020
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.

Evidation Health

Series D in 2020
Evidation Health develops a health data analytics platform that collects and analyzes continuous behavior data alongside healthcare information to enhance health outcomes. Founded in 2012 and headquartered in San Mateo, California, the company utilizes raw, high-frequency data from various sources such as sensors, devices, and video to generate insights into health and disease. Its products include a Data Platform, which transforms everyday behavior data into actionable health measures, and Studies, a service for conducting real-world research that incorporates behavioral data to support clinical and commercial teams. Evidation Health connects digital health companies with healthcare providers and payers, facilitating a better understanding of how everyday behaviors influence health. The company's offerings also encompass health outcomes research, technology assessment, and predictive analytics services.

Arterys

Series C in 2020
Arterys Inc. is a technology company specializing in medical imaging analytics, aiming to enhance patient care through innovative solutions. Founded in 2007 and headquartered in San Francisco, California, with additional offices in Calgary and Paris, Arterys offers a cloud-based, AI-powered platform that enables radiologists to visualize and quantify blood flow in the body. Its product lineup includes Cardio AI for cardiac imaging, Lung AI for lung analysis, Liver AI for liver diagnostics, and Chest/MSK AI for detecting various thoracic and musculoskeletal conditions. The platform is fully web-based and FDA-cleared, providing clinicians with tools for automatic and interactive reporting. Additionally, the Arterys PHI Service allows physicians to access patient data remotely, further supporting efficient medical practices.

Syapse

Series F in 2020
Syapse, Inc. is a company that specializes in precision medicine through its software platform, which integrates and analyzes clinical, molecular, treatment, and outcomes data. This platform supports data-driven decision-making for healthcare executives, care teams, and researchers involved in precision medicine programs. One of its key offerings is the Syapse Learning Health Network, a global data-sharing network focused on oncology, which leverages real-world data to enhance clinical decision-making. By connecting health systems, life sciences companies, and regulators, Syapse aims to accelerate the generation of real-world evidence to improve cancer patient outcomes. Founded in 2008 and headquartered in San Francisco, California, Syapse is committed to ensuring that all cancer patients receive high-quality care through improved precision medicine initiatives.

Singular Genomics

Venture Round in 2019
Singular Genomics is a biotechnology company based in La Jolla, California, founded in 2016. It specializes in developing advanced gene sequencing technologies utilizing fluorescing molecular tags and novel next-generation sequencing and multiomics approaches. The company aims to empower researchers and clinicians through its innovative products, which include the G4 Sequencing Platform for next-generation sequencing and the PX Integrated Solution for single-cell analysis, spatial analysis, and proteomics. Singular Genomics is strategically located within a prominent biotech hub, adjacent to esteemed institutions such as the Salk Institute and UC San Diego, fostering collaboration and innovation in the rapidly growing genomics field. Its product offerings cater to a wide range of applications, including basic biology, oncology, and immunology, positioning the company as a key player in the life sciences sector.

Providence Medical Technology

Venture Round in 2018
Providence Medical Technology is a privately-held medical device company focused on innovative solutions for cervical spinal conditions. The company has pioneered a proprietary approach to cervical fusion and has developed surgical instrumentation and implants that offer unique benefits to the $2 billion worldwide cervical spine market. The Providence family of products includes the DTRAX® Spinal Instrumentation System, CAVUX® intervertebral implants, and the ALLY® line of bone and facet screws. All products are shipped-sterile and single-use to maximize perioperative efficiency and ensure consistent quality and performance.

Vertos Medical

Venture Round in 2017
Vertos Medical Inc. is a medical device company based in Aliso Viejo, California, founded in 2005 by Dr. Dave Solsberg and Dr. Don Schomer. The company specializes in developing minimally invasive treatments for lumbar spinal stenosis (LSS), a common spinal condition. Its flagship product, the mild device, facilitates an outpatient treatment that is fluoroscopically guided and does not require the use of implants. This device includes components such as tissue sculptors, portals, trocars, and surgical clamps, allowing physicians to perform lumbar decompression procedures with local anesthesia. By restoring space in the spinal canal and alleviating pressure on the nerves, Vertos Medical's solutions aim to improve patient mobility and quality of life. The company's devices are primarily offered in the United States.

ClearCorrect

Private Equity Round in 2016
ClearCorrect, LLC, founded in 2006 and based in Round Rock, Texas, specializes in the development and manufacturing of clear dental aligners designed to straighten teeth without the use of traditional metal braces. The company offers a series of custom, removable aligners that are prescribed and fitted by dental professionals, allowing for gradual teeth movement toward the desired alignment. ClearCorrect's approach emphasizes patient comfort and convenience, providing an effective solution for orthodontic treatment that is both affordable and compatible with dental practices. Since becoming a subsidiary of Straumann Holding AG in 2017, ClearCorrect continues to focus on innovative dental solutions that enhance patient care and satisfaction.

Bluesight

Series B in 2015
Bluesight is a software tool developed by Kit Check, Inc. that focuses on substance tracking and drug diversion detection within hospital pharmacies. This platform is part of a broader suite of cloud-based solutions designed to enhance the efficiency of pharmacy operations, including medication tracking and kit automation. Kit Check, Inc. utilizes Internet of Things (IoT) technology to significantly reduce kit replenishment time while increasing accuracy and minimizing errors. The company serves hospitals and pharmacies throughout the United States and Canada, tracking a substantial volume of medication, which contributes to improved supply chain management and operational safety. Founded in 2011 and based in Washington, D.C., Kit Check continues to innovate in the healthcare technology sector.

AcuFocus

Venture Round in 2014
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to assist presbyopic patients in restoring their near vision while preserving distance clarity. Additionally, AcuFocus provides the IC-8 IOL, a small aperture lens that accommodates a range of vision for cataract patients. The AcuTarget HD system serves as a diagnostic and surgical planning tool, aiding in the optimal treatment selection for various eye conditions, including LASIK and dry eye. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, thereby serving a global clientele of physicians and patients. Founded in 2001, AcuFocus continues to focus on advancing solutions for presbyopia and related vision issues.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.